Abstract
Donor-specific transplantation tolerance, defined as the indefinite survival of an allograft (Tx) in the absence of immunosuppression, remains the elusive goal in clinical organ transplantation. Indeed, the major benefits in transplant patients are over-shadowed by late chronic rejection as well as side-effects resulting from continual therapy. This study was designed to analyze the tolerogenic effects of CD4-targeted therapy with a nondepleting (RIB-5/2) MAb in a well-defined model of accelerated cardiac Tx rejection in sensitized rat recipients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
